{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:22:46Z","timestamp":1789017766769,"version":"build-2803163510"},"reference-count":30,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Epstein-Barr virus (EBV)\u2013DNA was prospectively analyzed in plasma and mononuclear cells (MNCs) from peripheral blood in patients with extranodal natural killer (NK)\/T-cell lymphoma, nasal type, to evaluate the clinical significance for diagnosis, monitoring the tumor burden, and prognostication. Thirty-three patients were enrolled, and 32 were evaluable. Pretreatment plasma and MNC EBV-DNA was detectable in 14 (range, 50-71 000 copies\/mL) and 6 patients (range, 20-780 copies\/\u03bcg DNA), respectively, and both were well correlated (r = 0.8741, P &lt; .0001). Detectable plasma EBV-DNA was associated with higher clinical stage (P = .02), presence of B symptoms (P = .02), worse performance status (P = .02), and higher serum soluble IL-2 receptor level (P &lt; .0001). Twenty-two patients attained complete response. Plasma EBV-DNA level was significantly higher in nonresponders than in responders (mean, 16 472 vs 2 645 copies\/mL; P = .02). Multivariate analysis showed clinical stage (hazard ratio, 9.0; 95% confidence interval, 1.8%-45.0%) and pretreatment plasma EBV-DNA (hazard ratio, 10.6; 95% confidence interval, 1.3%-87.0%) were significant prognostic factors. Three-year overall survival of plasma EBV-DNA positive and negative patients was 42.9% and 94.4%, respectively (P = .0009). Plasma was a preferable sample for this purpose in NK\/T-cell lymphoma, nasal type, and EBV-DNA level was a good indicator for response and overall survival.<\/jats:p>","DOI":"10.1182\/blood-2011-05-354142","type":"journal-article","created":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T04:27:23Z","timestamp":1318048043000},"page":"6018-6022","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":169,"title":["Prospective measurement of Epstein-Barr virus\u2013DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type"],"prefix":"10.1182","volume":"118","author":[{"given":"Ritsuro","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tokyo University School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tokyo University School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Virology, Hokkaido University Graduate School of Medicine, Sapporo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Harabuchi","sequence":"additional","affiliation":[{"name":"Department of Otorhinoraryngology, Asahikawa Medical University, Asahikawa, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Isobe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Gomyo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Cancer Center, Kobe, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagaoka Red Cross Hospital, Nagaoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fujita Health University School of Medicine, Fujita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Hyo","sequence":"additional","affiliation":[{"name":"Department of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukuoka University School of Medicine, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisei","family":"Kawa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Oshimi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the NK-cell Tumor Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111808563188900_B1","first-page":"285","article-title":"Extranodal NK\/T-cell lymphoma, nasal type.","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Chan","year":"2008"},{"issue":"2","key":"2019111808563188900_B2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hon.847","article-title":"Extranodal NK\/T-cell lymphoma: diagnosis and treatment cues.","volume":"26","author":"Suzuki","year":"2008","journal-title":"Hematol Oncol"},{"issue":"5","key":"2019111808563188900_B3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"1","key":"2019111808563188900_B4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00000478-199601000-00012","article-title":"Report of the Workshop on Nasal and Related Extranodal Angiocentric T\/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology.","volume":"20","author":"Jaffe","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"8682","key":"2019111808563188900_B5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0140-6736(90)90002-M","article-title":"Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma.","volume":"335","author":"Harabuchi","year":"1990","journal-title":"Lancet"},{"issue":"8","key":"2019111808563188900_B6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/0046-8177(94)90244-5","article-title":"In situ localization of Epstein-Barr virus encoded RNA in non-nasal\/nasopharyngeal CD56-positive and CD56-negative T-cell lymphomas.","volume":"25","author":"Tsang","year":"1994","journal-title":"Hum Pathol"},{"issue":"9","key":"2019111808563188900_B7","first-page":"2028","article-title":"Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients.","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"2019111808563188900_B8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9440(10)61713-0","article-title":"Detection of cyclin D1 overexpression by real-time reverse-transcriptase mediated quantitative polymerase chain reaction for the diagnosis of mantle cell lymphoma.","volume":"159","author":"Suzuki","year":"2001","journal-title":"Am J Pathol"},{"issue":"14","key":"2019111808563188900_B9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111808563188900_B10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111808563188900_B11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood.V98.2.280","article-title":"Clinical and virologic characteristics of chronic active Epstein-Barr virus infection.","volume":"98","author":"Kimura","year":"2001","journal-title":"Blood"},{"issue":"13","key":"2019111808563188900_B12","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood.V98.13.3739","article-title":"Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load.","volume":"98","author":"Silins","year":"2001","journal-title":"Blood"},{"issue":"5","key":"2019111808563188900_B13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V97.5.1165","article-title":"Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.","volume":"97","author":"Stevens","year":"2001","journal-title":"Blood"},{"issue":"11","key":"2019111808563188900_B14","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1128\/JCM.41.11.5245-5249.2003","article-title":"Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR.","volume":"41","author":"Wadowsky","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"2","key":"2019111808563188900_B15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcv.2003.10.002","article-title":"Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma.","volume":"30","author":"Fafi-Kremer","year":"2004","journal-title":"J Clin Virol"},{"issue":"7","key":"2019111808563188900_B16","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1128\/JCM.02308-06","article-title":"Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood.","volume":"45","author":"Hakim","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2019111808563188900_B17","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/JCM.39.4.1211-1216.2001","article-title":"Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen.","volume":"39","author":"Stevens","year":"2001","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2019111808563188900_B18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/(SICI)1097-0215(19990820)84:4<442::AID-IJC20>3.0.CO;2-J","article-title":"Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease.","volume":"84","author":"Gallagher","year":"1999","journal-title":"Int J Cancer"},{"issue":"1","key":"2019111808563188900_B19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2000.02344.x","article-title":"Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies.","volume":"111","author":"Lei","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111808563188900_B20","first-page":"29","article-title":"Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer\/T-cell lymphoma.","volume":"8","author":"Lei","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111808563188900_B21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2003-12-4197","article-title":"Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients.","volume":"104","author":"Au","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111808563188900_B22","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-05-2008","article-title":"Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.","volume":"12","author":"Gandhi","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111808563188900_B23","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"issue":"12","key":"2019111808563188900_B24","first-page":"4675","article-title":"Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients.","volume":"61","author":"Sozzi","year":"2001","journal-title":"Cancer Res"},{"issue":"4","key":"2019111808563188900_B25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111808563188900_B26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdp418","article-title":"Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type.","volume":"21","author":"Suzuki","year":"2010","journal-title":"Ann Oncol"},{"issue":"33","key":"2019111808563188900_B27","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"35","key":"2019111808563188900_B28","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study.","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111808563188900_B29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705244","article-title":"Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms.","volume":"37","author":"Suzuki","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2019111808563188900_B30","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbmt.2008.09.014","article-title":"Autologous hematopoietic stem cell transplantation in extranodal NK\/T-cell lymphoma: a multinational, multicenter, matched controlled study.","volume":"14","author":"Lee","year":"2008","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/23\/6018\/1344921\/zh804911006018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/23\/6018\/1344921\/zh804911006018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T15:01:30Z","timestamp":1574089290000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/23\/6018\/29116\/Prospective-measurement-of-EpsteinBarr-virusDNA-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,1]]},"references-count":30,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-354142","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,1]]}}}